GTC presented abstracts at AACR 2023
GTC’s posters from 2023 Convention of American Association for Cancer Research are now available to be downloaded. Please reach out with any questions.
Predicting PD-L1 Status in Solid Tumors Using Transcriptomic Data and Artificial Intelligence Algorithms
The Molecular Landscape of Premenopausal Versus Postmenopausal Breast Cancer in Patients Without Inherited Predisposition Mutations
Real-world transcriptomic biomarkers as replacement for immunohistochemistry and FISH studies in breast cancer
Read more Articles and News from GTC
Genomic Testing Cooperative Presents at ASCO meeting Studies Demonstrating the Power of its Liquid Biopsy and Tissue-Based Targeted Transcriptomic Approach when Combined with Artificial Intelligence
Irvine, California– May 31, 2023 – Genomic Testing Cooperative, LCA (GTC) announced that it will be presenting at the 2023 American Society of Clinical Oncology
New publication on how cfRNA and AI are advancing LBx
GTC has a new publication in Heliyon titled “The Potential of Cell-Free RNA in Liquid Biopsy: Comprehensive Analysis of Mutation Profile, Chromosomal Abnormalities, and Immune
Genomics beyond drug selection: Using DNA and RNA data
This workshop is designed for oncologists, pathologists, oncology nurses and other medical professionals involved in patient care for cancer patients. Saturday, September 23 · 7am – 5pm CDT
AACR 23 Posters
GTC presented abstracts at AACR 2023 GTC’s posters from 2023 Convention of American Association for Cancer Research are now available to be downloaded. Please reach
Sysmex Inostics and Genomic Testing Cooperative Form Partnership to Accelerate Therapeutic Discovery and Development
Baltimore, MD and Irvine, CA, April 13, 2023, Sysmex Inostics Inc., a subsidiary of Japan’s Sysmex Corporation and Baltimore-based biotechnology firm, and Genomic Testing Cooperative
Genomic Testing Cooperative to Present at the AACR 2023 Meeting
Demonstrating Reliability of Targeted Transcriptomic Profiling in Predicting Levels of HER2, ER, PD-L1 and Other Immunohistochemistry-based Biomarkers when Combined with Artificial Intelligence Irvine, California– April